Banca de DEFESA: OTAVIO AUGUSTO CARVALHO DE OLIVEIRA SANTOS

Uma banca de DEFESA de MESTRADO foi cadastrada pelo programa.
DISCENTE : OTAVIO AUGUSTO CARVALHO DE OLIVEIRA SANTOS
DATA : 26/11/2020
HORA: 14:30
LOCAL: Online
TÍTULO:

 Type B natriuretic peptide (BNP, pro-BNP, and NT-pro-BNP) as 

a biomarker of heart failure to be incorporated into the clinical practice of the Unified Health 

System – SUS/Brazil: evaluation of health technologies.

PALAVRAS-CHAVES:

Heart Failure; Biomarkers; Type B Natriuretic Peptide; BNP; health technology assessment for SUS.

PÁGINAS: 55
GRANDE ÁREA: Ciências da Saúde
ÁREA: Farmácia
SUBÁREA: Análise Toxicológica
RESUMO:

Introduction: Heart failure is the final clinical manifestation of several cardiac pathologies. BNP is a neurohormone secreted by the ventricles in response to volume expansion and cardiac overload and was considered an important biochemical marker for diagnosis, evaluation, and prognosis of patients with congestive heart failure. Objective: To show the feasibility of implementing the determination of type B natriuretic peptide (BNP, pro-BNP and NT-pro-BNP) in the clinical practice of the Unified Health System – SUS/Brazil, given the association of these biomarkers with the clinic of patients with heart failure and the economic viability added by this diagnostic support procedure. Methodology: Observational, cross-sectional study, carried out with a convenience sampling, from the collection of data in medical records and in the laboratory information system from patients with congestive heart failure, admitted to the Hospital da Bahia, as well as data from patients from the Ana Nery Hospital / UFBA, and Clínica Santa Helena/Camaçari, Bahia. Results: From 55 patients evaluated, 89% (n = 49) had high BNP values, 71.4% (n = 35) with heart failure. The remainder (28.6%), despite not having heart failure, BNP was above the cut-off values, due to heart disease, in addition to other associated comorbidities that also elevate BNP, such as sepsis, kidney and respiratory failure. Regarding implementation costs, quotations in the national market, the values for determining BNP, (single test) varied between 48.50 and 177.00 reais. Depending on the methodology and number of tests to be realized, if the BNP kit can be adequately purchased, to access the estimated values, excellent cost-benefit ratio would be achieved, that is, between 13.64 and 27.00 reais each test determination. Conclusion: Therefore, based on all currently available information, implementing the BNP/NT-proBNP biomarkers determination within the scope of SUS is economically viable, will speed up diagnosis, prognosis, better patient follow-up and clinical conduct so far implemented for heart failure.

MEMBROS DA BANCA:
Presidente - 1490663 - RICARDO DAVID COUTO
Interno - 2055299 - ANA LEONOR PARDO CAMPOS GODOY
Externo ao Programa - 2556460 - PABLO DE MOURA SANTOS